Where Does Direct-to-Patient Fit in a Post-COVID World?
Applied Clinical Trials, Andrea Zobel
As we look forward, questions exist about how the use of direct-to-patient model will evolve—and what is needed to ensure the success of these trials in a rapidly evolving healthcare and clinical trial landscape. In the following Q&A, Andrea Zobel, PhD, Senior Director of Personalized Supply Chain at AmerisourceBergen’s World Courier, a global specialty logistics provider, and Graham Wylie, MBBS, Executive Chairman & Founder of the Medical Research Network (MRN), discuss the demand for decentralized clinical trials (DCTs), the unique challenges and considerations for implementing the model around the world, and how the emergence of technology and data solutions will affect DCT moving forward.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.